Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029

1.1 Liquid Biopsy Market - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales, and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
1.4 Impact of Artificial Intelligence on Liquid Biopsy Market

2.1 What is Liquid Biopsy?
2.2 The Sequencing Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics

3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Instrumentation Supplier
3.1.4 Chemical/Reagent Supplier
3.1.5 Pathology Supplier
3.1.6 Independent Clinical Laboratory
3.1.7 Public National/regional Laboratory
3.1.8 Hospital Laboratory
3.1.9 Physicians Office Lab (POLS)
3.1.10 Audit Body
3.1.11 Certification Body
3.2 Using Biopsies
3.2.1 Cancer
3.2.2 Precancerous conditions
3.2.3 Inflammatory conditions
3.3 Biopsy Sites
3.4 The Situation Today - Biopsy Analysis
3.5 Evidence of Cancer - Liquid Biopsy Technology
3.5.1 The Big Picture on Liquid Biopsy Technology
3.5.2 The Role of CTCs
3.5.3 Application of CTCs
3.5.4 CellSearch Detection- Ultimate Sensitivity
3.5.5 Epic Sciences Detection- Imaging Takes the Lead
3.5.6 Maintrac Detection - The Microscope
3.5.7 Other Methods
3.5.8 ctDNA Role
3.5.9 ctDNA Applications
3.5.10 Exosomes and Micro Vesicles - New Kid on the Block
3.5.11 The Multiple Play
3.6 Cancer Treatment Protocol Under Siege
3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
3.6.2 The Cancer Screening Market Opportunity
3.6.2.1 GRAIL - What Is It?
3.6.3 Cancer Management vs. Diagnosis
3.6.3.1 The Role of Risk Assessment
3.6.3.2 Managing Therapy
3.6.3.3 Monitoring Disease - What Is It?
3.6.4 Phases of Adoption - Looking into The Future
3.6.5 The Promise of Liquid Biopsy
3.7 Structure of Industry Plays a Part
3.7.1 Hospital Testing Share
3.7.2 Economies of Scale
3.7.2.1 Hospital vs. Central Lab
3.7.3 Physician Office Lab’s
3.7.4 Physician’s and POCT

4.1 Factors Driving Growth
4.1.1 Non-Invasive Game Changer
4.1.2 Lower Cost
4.1.3 Greater Accuracy
4.1.4 Wide Range of Potential Uses
4.1.5 Aging Population
4.2 Factors Limiting Growth
4.2.1 Lower prices
4.2.2 Lack of Standards
4.2.3 Protocol Resistance
4.2.4 Initial Adoption Cost
4.2.5 Conclusion
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 Bioinformatics Plays a Role
4.4 Diagnostic Technology Development
4.4.1 Next Generation Sequencing Fuels a Revolution
4.4.2 Impact of NGS on pricing
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World
4.4.5 Biochips/Giant magneto resistance based assay

5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Liquid Biopsy Firm QCDx Closes Financing
5.3 LabCorp Launches Liquid Biopsy
5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing
5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M
5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform
5.7 Syantra Closes Financing
5.8 Concerns Over Grail Test Effectiveness
5.9 Guardant Health Sues Tempus for Patent Infringement
5.10 Delfi Dx Liquid Biopsy Technology Shows Promise
5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx
5.12 Grail Details TBE Method for Cancer Monitoring
5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage
5.14 Personalis NeXT Personal Dx Early-Access Program
5.15 Liquid Biopsy Shortens Time to Treatment
5.16 Guardant Health MRD Test Garners Coverage
5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic
5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test
5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test
5.21 Sophia Genetics to Commercialize Liquid Biopsy Test
5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M
5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform
5.25 PamGene Expanding Liquid Biopsy Assays
5.26 Liquid Biopsy Firm Hedera Dx Raises €14M
5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
5.28 Precision Oncology Dx Access Varies Widely in Europe
5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
5.31 BillionToOne Launches First Liquid Biopsy Products
5.32 Dxcover Advances Multicancer Detection Platform
5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
5.34 Illumina Sues Guardant Health Over Patents
5.35 Invitae to Expand Cancer Testing Portfolio
5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator
5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
5.42 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
5.44 Bio-Techne to Acquire Asuragen for up to $320M
5.45 Personalis Broadens Liquid Biopsy Offering
5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test
5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
5.49 Liquid Biopsy NGS Panels - Diverse Test Claims
5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays
5.51 Natera Liquid Biopsy Test Coverage to Expand
5.52 Freenome Closes Financing to Support Early Cancer Detection Trial
5.53 C$2.6M Liquid Biopsy Initiative
5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
5.55 Liquid Biopsy Shows Promise as Screen for Cancers
5.56 Inivata launches RaDaR™ for the detection of residual disease and recurrence
5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer
5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6.1 Admera Health, LLC
6.2 Abbott Laboratories
6.3 AccuraGen Inc.
6.4 Acuamark Diagnostics
6.5 Agilent
6.6 Amoy Diagnostics Co., Ltd.
6.7 Anchor Dx
6.8 ANGLE plc
6.9 Applied DNA Sciences
6.10 ARUP Laboratories
6.11 AVIVA Systems Biology
6.12 Baylor Miraca Genetics Laboratories
6.13 Beckman Coulter Diagnostics (Danaher)
6.14 Becton, Dickinson and Company
6.15 Berkley Lights
6.16 BGI Genomics Co. Ltd
6.17 BillionToOne
6.18 Bioarray Genetics
6.19 Biocartis
6.20 Biocept, Inc.
6.21 Biodesix Inc.
6.22 BioFluidica
6.23 Biolidics Ltd
6.24 bioMérieux Diagnostics
6.25 Bioneer Corporation
6.26 Bio-Rad Laboratories, Inc
6.27 Bio-Techne
6.28 Bioview
6.29 Burning Rock
6.30 Cardiff Oncology
6.31 CareDx
6.32 Caris Molecular Diagnostics
6.33 CellCarta
6.34 CellMax Life
6.35 Cepheid (Danaher)
6.36 Circulogene
6.37 Cizzle Biotech
6.38 Clearbridge Biomedics
6.39 Clinical Genomics
6.40 Cytolumina Technologies Corp.
6.41 Datar Cancer Genetics Limited
6.42 Diagnologix LLC
6.43 Dxcover
6.44 Element Biosciences
6.45 Enzo Biochem
6.46 Epic Sciences
6.47 Epigenomics AG
6.48 Eurofins Scientific
6.49 Exact Sciences
6.50 Fluxion Biosciences (Cell Microsystems)
6.51 Freenome
6.52 Fyr Diagnostics
6.53 GeneFirst Ltd.
6.54 Genetron Holdings
6.55 GILUPI Nanomedizin
6.56 Guardant Health
6.57 HansaBiomed
6.58 Haystack Oncology (Quest Dx)
6.59 iCellate
6.60 ICON PLC
6.61 Illumina
6.62 Incell Dx
6.63 Inivata
6.64 INOVIQ
6.65 Invitae Corporation
6.66 J&J Innovative Medicine
6.67 Lucence Health
6.68 Lunglife AI Inc
6.69 MDNA Life SCIENCES, Inc.
6.70 MDx Health
6.71 Menarini Silicon Biosystems
6.72 Mesa Laboratories, Inc.
6.73 Millipore Sigma
6.74 Miltenyi Biotec
6.75 miR Scientific
6.76 Myriad Genetics
6.77 Nanostring
6.78 NantHealth, Inc.
6.79 Natera
6.80 NeoGenomics
6.81 Novogene
6.82 On-Chip Biotechnologies
6.83 Oncocyte
6.84 OncoDNA
6.85 Oncimmune
6.86 Oxford Nanopore Technologies
6.87 PamGene
6.88 Panagene
6.89 Personalis
6.90 PGDx (Labcorp)
6.91 PrecisionMed
6.92 Predicine
6.93 Predictive Oncology
6.94 Prenetics
6.95 Promega
6.96 Qiagen
6.97 Rarecells SAS
6.98 RareCyte
6.99 Revvity
6.100 Roche Diagnostics
6.101 Saga Diagnostics
6.102 Screencell
6.103 Siemens Healthineers
6.104 simfo GmbH
6.105 Singlera Genomics Inc.
6.106 Singular Genomics
6.107 Standard BioTools
6.108 Stilla Technologies
6.109 Superfluid Dx
6.110 Sysmex Inostics
6.111 Tempus Labs, Inc.
6.112 Thermo Fisher Scientific
6.113 Todos Medical
6.114 Ultima Genomics
6.115 Veracyte
6.116 VolitionRX
6.117 Vortex Biosciences

7.1 Global Market Overview by Country
7.1.1 Table - Global Market by Country
7.1.2 Chart - Global Market by Country
7.2 Global Market by Cancer - Overview
7.2.1 Table - Global Market by Cancer
7.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
7.2.3 Chart - Global Market by Cancer - Base Year
7.2.4 Chart - Global Market by Cancer - End Year
7.2.5 Chart - Global Market by Cancer - Share by Year
7.2.6 Chart - Global Market by Cancer - Segments Growth
7.3 Global Market by Usage - Overview
7.3.1 Table - Global Market by Usage
7.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
7.3.3 Chart - Global Market by Usage - Base Year
7.3.4 Chart - Global Market by Usage - End Year
7.3.5 Chart - Global Market by Usage - Share by Year
7.3.6 Chart - Global Market by Usage - Segments Growth
7.4 Global Market by Place - Overview
7.4.1 Table - Global Market by Place
7.4.2 Chart - Global Market by Place - Base/Final Year Comparison
7.4.3 Chart - Global Market by Place - Base Year
7.4.4 Chart - Global Market by Place - End Year
7.4.5 Chart - Global Market by Place - Share by Year
7.4.6 Chart - Global Market by Place - Segments Growth
7.5 Global Market by Marker - Overview
7.5.1 Table - Global Market by Marker
7.5.2 Chart - Global Market by Marker - Base/Final Year Comparison
7.5.3 Chart - Global Market by Marker - Base Year
7.5.4 Chart - Global Market by Marker - End Year
7.5.5 Chart - Global Market by Marker - Share by Year
7.5.6 Chart - Global Market by Marker - Segments Growth
7.6 Global Market by Product - Overview
7.6.1 Table - Global Market by Product
7.6.2 Chart - Global Market by Product - Base/Final Year Comparison
7.6.3 Chart - Global Market by Product - Base Year
7.6.4 Chart - Global Market by Product - End Year
7.6.5 Chart - Global Market by Product - Share by Year
7.6.6 Chart - Global Market by Product - Segments Growth

8.1 Breast
8.1.1 Table Breast - by Country
8.1.2 Table Breast - by Country, Price
8.1.3 Table Breast - by Country Volume
8.1.4 Chart - Breast Growth
8.2 Colorectal
8.2.1 Table Colorectal - by Country
8.2.2 Table Colorectal - by Country, Price
8.2.3 Table Colorectal - by Country, Volume
8.2.4 Chart - Colorectal Growth
8.3 Cervical
8.3.1 Table Cervical - by Country
8.3.2 Table Cervical - by Country, Price
8.3.3 Table Cervical - by Country, Volume
8.3.4 Chart - Cervical Growth
8.4 Lung
8.4.1 Table Lung - by Country
8.4.2 Table Lung - by Country, Price
8.4.3 Table Lung - by Country, Volume
8.4.4 Chart - Lung Growth
8.5 Prostate
8.5.1 Table Prostate - by Country
8.5.2 Table Prostate - by Country, Price
8.5.3 Table Prostate - by Country, Volume
8.5.4 Chart - Prostate Growth
8.6 Other
8.6.1 Table Other - by Country
8.6.2 Table Other - by Country, Price
8.6.3 Table Other - by Country, Volume
8.6.4 Chart - Other Growth

9.1 Screening
9.1.1 Table Screening - by Country
9.2 Chart - Screening Growth
9.3 Diagnostic
9.3.1 Table Diagnostic - by Country
9.3.2 Chart - Diagnostic Growth
9.4 Therapy
9.4.1 Table Therapy - by Country
9.4.2 Chart - Therapy Growth
9.5 Monitor
9.5.1 Table Monitor - by Country
9.5.2 Chart - Monitor Growth

10.1 Hospital Lab
10.1.1 Table Hospital Lab - by Country
10.1.2 Chart - Hospital Lab Growth
10.2 Lab Service
10.2.1 Table Lab Service - by Country
10.2.2 Chart - Lab Service Growth
10.3 Lab Outpatient
10.3.1 Table Lab Outpatient - by Country
10.3.2 Chart - Lab Outpatient Growth
10.4 Other Lab
10.4.1 Table Other Lab - by Country
10.4.2 Chart - Other Lab Growth

11.1 Circulating Tumor Cell
11.1.1 Table Circulating Tumor Cell - by Country
11.1.2 Chart - Circulating Tumor Cell Growth
11.2 Cell Free DNA
11.2.1 Table Cell Free DNA - by Country
11.2.2 Chart - Cell Free DNA Growth
11.3 Vesicle
11.3.1 Table Vesicle - by Country
11.3.2 Chart - Vesicle Growth
11.4 Other Marker
11.4.1 Table Other Marker - by Country
11.4.2 Chart - Other Marker Growth

12.1 Kits
12.1.1 Table Kits - by Country
12.1.2 Chart - Kits Growth
12.2 Instruments
12.2.1 Table Instruments - by Country
12.2.2 Chart - Instruments Growth
12.3 Service
12.3.1 Table Service - by Country
12.3.2 Chart - Service Growth

13.1 Growth of Approved IVD Test Menu
13.2 Growth of Approved Average IVD Test Fee
13.3 The Most Used IVD Assays
13.4 The Highest Grossing Assays
13.5 Laboratory Fees Schedule